Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Leonardo Bruno Mina
Observed names:
L. Mina,
Leonardo B. Mina,
Leonardo Mina
Institution:
MedSIR (Spain)
Observed institutions:
Universitat Autònoma de Barcelona,
Universitat Pompeu Fabra,
Instituto de Salud Carlos III,
MedSIR (Spain),
Centre for Biomedical Network Research on Rare Diseases
ORCID:
0000-0002-2289-4936
Observed ORCID:
0000-0002-2289-4936
OpenAlex ID:
A5088747102
Translation and replication of hepatitis C virus genomic RNA depends on ancient cellular proteins that control mRNA fates
2009
·
Nicoletta Scheller
, Leonardo Bruno Mina
, et al.
·
Proceedings of the National Academy of Sciences
·
154
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
2022
·
Marta Palafox
, Laia Monserrat
, et al.
·
Nature Communications
·
150
PDF
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
2024
·
José Manuel Pérez-García
, Javier Cortés
, et al.
·
The Lancet
·
133
Germline Mutations in FAN1 Cause Hereditary Colorectal Cancer by Impairing DNA Repair
2015
·
Nuria Seguí
, Leonardo B. Mina
, et al.
·
Gastroenterology
·
119
PDF
Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
2022
·
Joan Albanell
, José Manuel Pérez-García
, et al.
·
Clinical Cancer Research
·
43
PDF
On the role of FAN1 in Fanconi anemia
2012
·
Juan P. Trujillo
, Leonardo B. Mina
, et al.
·
Blood
·
43
Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study
2024
·
Xavier García Del Muro
, David Páez López-Bravo
, et al.
·
European Urology Oncology
·
31
LBA23 ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2- ABC) with aggressive disease criteria
2024
·
J. de la Haba Rodriguez
, J. Cortés
, et al.
·
Annals of Oncology
·
29
PDF
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
2022
·
Serena Di Cosimo
, José Manuel Pérez-García
, et al.
·
The Oncologist
·
28
Hepatitis C virus RNA recombination in cell culture
2011
·
Jochen Reiter
, Gemma Pérez-Vilaró
, et al.
·
Journal of Hepatology
·
23
Comparing [18F]FDG–positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial
2025
·
J.J. García-Mosquera
, J.M. Pérez-García
, et al.
·
ESMO Open
·
8
Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study
2024
·
Alfonso Cortés
, Elena López-Miranda
, et al.
·
The Breast
·
7
PDF
Profiling the gut and oral microbiota of hormone receptor-positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin
2024
·
Nancy MY Teng
, Andrea Malfettone
, et al.
·
Microbiome Research Reports
·
7
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
2022
·
Marta Palafox
, Laia Monserrat
, et al.
·
Nature Communications
·
7
PDF
Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study
2022
·
Ana López González
, Sonia Del Barco Berrón
, et al.
·
Cancers
·
5
PDF
Human epidermal growth factor receptor 2 (HER2) expression dynamics between diagnosis and recurrence in patients with breast cancer using artificial intelligence and electronic health records: the RosHER study
2025
·
E. López-Miranda
, P. Tolosa-Ortega
, et al.
·
ESMO Real World Data and Digital Oncology
·
4
PDF
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial
2025
·
Joan Albanell
, Angelo Gámez Pozo
, et al.
·
npj Breast Cancer
·
3
PDF
Phase II study of the efficacy of retifanlimab (Rf) (INCMGA00012) in penile squamous cell carcinoma (PSqCC): ORPHEUS final analysis.
2023
·
Xavier Garcia del Muro
, M. Andres Cuellar
, et al.
·
Journal of Clinical Oncology
·
3
Abstract PO2-15-06: ctDNA-based DNADX in hormone receptor-positive and HER2-negative (HR+/HER2-) advanced breast cancer following endocrine therapy and CDK4/6 inhibition: a correlative analysis from the randomized phase 2 PARSIFAL trial
2024
·
Fara Brasó-Maristany
, Javier Cortés
, et al.
·
Cancer Research
·
1
271P Eribulin (E) plus endocrine therapy (ET) in patients (pts) with HR[+]/HER2[-] metastatic breast cancer (mBC) after progression on previous ET: The REVERT study
2022
·
A. Lopez Gonzalez
, S. Del Barco Berron
, et al.
·
Annals of Oncology
·
1
PDF
Artificial intelligence for clinical data extraction from EHRs in breast cancer trials: the MIRROR study
2026
·
Carlos Luis Parra-Calderón
, Leonardo Mina
, et al.
·
npj Breast Cancer
PDF
Multimodal Artificial Intelligence Predicts Pathological Response and Prognosis in HER2-Positive Early Breast Cancer Treated with Chemotherapy De-escalation Strategies: Analyses from PHERGain and PHERGain-2 Trials
2026
·
Manuel Ruiz Borrego
, Javier Cortés
, et al.
·
medRxiv
PDF
Supplementary Figure S3 from Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
2025
·
Joan Albanell
, José Manuel Pérez-García
, et al.
Supplementary Figure S4 from Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
2025
·
Joan Albanell
, José Manuel Pérez-García
, et al.
Supplementary Tables S1-14 from Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
2025
·
Joan Albanell
, José Manuel Pérez-García
, et al.
Show more works
View as search
Works count:
40
Citation count:
799
H-index:
10
I10-index:
10
Year
Topic
Type